OrbiMed’s RxSight RXST Stock Holding History

OrbiMed’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,202,833	Closed	-$20.1M	–	134
2023 Q1	$20.1M	Hold	1,202,833	–	–	0.39%	66
2022 Q4	$15.2M	Hold	1,202,833	–	–	0.29%	69
2022 Q3	$14.4M	Sell	1,202,833 -180,667	-13%	-$2.48M	0.27%	77
2022 Q2	$19.5M	Hold	1,383,500	–	–	0.35%	63
2022 Q1	$17.1M	Hold	1,383,500	–	–	0.28%	72
2021 Q4	$15.6M	Buy	1,383,500 +133,500	+11%	+$1.6M	0.2%	98
2021 Q3	$15.8M	Buy	+1,250,000	New	+$17.2M	0.17%	107

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.89B AUM 151.53% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OrbiMed's RXST Position: Q2 2023 in Review

OrbiMed sold out of RxSight (RXST) in Q2 2023, closing a stake of 1,202,833 shares — an estimated $20.1M sold.

OrbiMed first reported a position in RXST in Q3 2021 and held it in 7 quarters. The position peaked at $20.1M in Q1 2023. 115 funds tracked by Wall St. Rank hold RXST as of Q2 2023.

OrbiMed reported no remaining RxSight position as of Q2 2023 after selling out during the quarter.
OrbiMed sold 1,202,833 RxSight shares in Q2 2023, an estimated $20.1M.
OrbiMed first reported a position in RxSight in Q3 2021 and held it in 7 quarters.
OrbiMed's RxSight position peaked at $20.1M in Q1 2023.
115 funds tracked by Wall St. Rank held RxSight as of Q2 2023.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.